Skip to main content

Table 4 Switching patterns of anchor drug class in ART regimens by switching timing from 2011 to 2016

From: Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database

Timing of switch (n = 268)

Anchor drug class in the second regimen

Switch < 1 year after starting the first regimen

Switch ≥1 year after starting the first regimen

Anchor drug class in the first regimen

NNRTI

PI

INSTI

NNRTI

PI

INSTI

n

%

(95% CIa)

n

%

(95% CIa)

n

%

(95% CIa)

n

%

(95% CIa)

n

%

(95% CIa)

n

%

(95% CIa)

NNRTI

4

8.3

(3.3–19.6)

44

91.7

(80.4–96.7)

0

0.0

35

100.0

(90.1–100.0)

PI

2

2.5

(0.7–8.6)

79

97.5

(91.4–99.3)

2

2.5

(0.7–8.6)

79

97.5

(91.4–99.3)

INSTI

5

35.7

(16.3–61.2)

8

57.1

(32.6–78.6)

4

50.0

(21.5–78.5)

4

50.0

(21.5–78.5)

  1. ART antiretroviral therapy, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitor, CI confidence interval
  2. Two patients who had multiple prescription records of anchor drug class in the second regimen were excluded from the analysis
  3. Entry inhibitor was excluded from the table as only two patients were prescribed an entry inhibitor in the first/second ART regimen
  4. aWilson score